Precision sirolimus dosing in children: The potential for model-informed dosing and novel drug monitoring
Frontiers in Pharmacology · 20.03.2023 · 14
DOI: 10.3389/fphar.2023.1126981 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 20.03.2023. Verfasst von Guofang Shen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematologic Malignancies Translational Sciences, City of Hope, and Department of Hematopoietic Cell Transplantation, City of Hope Medic…. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 195 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIGMS NIH HHS, American Cancer Society.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
The mTOR inhibitor sirolimus is prescribed to treat children with varying diseases, ranging from vascular anomalies to sporadic lymphangioleiomyomatosis to transplantation (solid organ or hematopoietic cell). Precision dosing of sirolimus using therapeutic drug monitoring (TDM) of sirolimus concentrations in whole blood drawn at the trough (before the next dose) time-point is the current standard of care. For sirolimus, trough concentrations are only modestly correlated with the area under the curve, with R 2 values ranging from 0.52 to 0.84. Thus, it should not be surprising, even with the use of sirolimus TDM, that patients treated with sirolimus have variable pharmacokinetics, toxicity, and effectiveness. Model-informed precision dosing (MIPD) will be beneficial and should be implemented. The data do not suggest dried blood spots point-of-care sampling of sirolimus concentrations for precision dosing of sirolimus. Future research on precision dosing of sirolimus should focus on pharmacogenomic and pharmacometabolomic tools to predict sirolimus pharmacokinetics and wearables for point-of-care quantitation and MIPD.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hematologic Malignancies Translational Sciences, City of Hope, and Department of Hematopoietic Cell Transplantation, City of Hope Medical Center, Duarte, CA, United States.
- Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles, CA, United States.
- Clinical Informatics, City of Hope Medical Center, Duarte, CA, United States.
- Division of Biostatistics, City of Hope, Duarte, CA, United States.
- Division of Engineering and Applied Science, Andrew and Peggy Cherng Department of Medical Engineering, California Institute of Technology, Pasadena, CA, United States.
Förderung
- NCI NIH HHS
- NIGMS NIH HHS
- American Cancer Society
- National Institutes of Health
Zitieren
APA
Shen, G., Moua, K. T. Y., Perkins, K., Johnson, D., Li, A., Curtin, P., Gao, W., & McCune, J. S. (2023). Precision sirolimus dosing in children: The potential for model-informed dosing and novel drug monitoring. Frontiers in Pharmacology, 14. https://doi.org/10.3389/fphar.2023.1126981
Vancouver
Shen G, Moua KTY, Perkins K, Johnson D, Li A, Curtin P, et al. Precision sirolimus dosing in children: The potential for model-informed dosing and novel drug monitoring. Frontiers in Pharmacology. 2023;14. doi:10.3389/fphar.2023.1126981
BibTeX
@article{Shen2023,
author = {Shen, Guofang and Moua, Kao Tang Ying and Perkins, Kathryn and Johnson, Deron and Li, Arthur and Curtin, Peter and Gao, Wei and McCune, Jeannine S},
title = {Precision sirolimus dosing in children: The potential for model-informed dosing and novel drug monitoring},
journal = {Frontiers in Pharmacology},
year = {2023},
volume = {14},
doi = {10.3389/fphar.2023.1126981}
}
EUVIMED